In earlier reports on visual outcome prior to the use of TNF-α inhibitors for the treatment of refractory BD uveitis, 20–74% of patients became legally blind with visual acuity of 20/200 or less within 10 years after the onset of uveitis (6, 7, 28–30). The gene discussed is TNF; the disease is uveitis.